FTC Asks Seagen and Pfizer for Additional Information on Proposed $43 Billion Merger

The Federal Trade Commission (FTC) has asked Pfizer and Seagen for more information on their proposed $43 billion merger, the Seattle biotech revealed (PDF) in a Securities and Exchange Comission (SEC) filing Friday.

This is the second round of documentation the antitrust regulator has requested from the companies since their deal was announced in March.

“Second requests require both parties to provide additional information to assess the legality of the transaction, though they can be broad in nature, investigating issues such as existing or potential competition, drug pricing or off-label usage of certain products,” SVB Securities wrote in a note to investors.

Read the source article at Fierce Pharma